MetaCap

Agios Pharmaceuticals (AGIO) vs ANI Pharmaceuticals (ANIP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agios Pharmaceuticals (AGIO) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 9.4% versus a loss of 14.0%. Over five years, ANIP leads with a +68.1% price change compared with -24.3% for AGIO. Agios Pharmaceuticals is the larger company by market cap ($1.65 billion vs $1.56 billion), about 1.1 times the size.

ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -764.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO+9.35%ANIP-14.01%
+79%+29%-20%
Nov 21, 20251 yearNov 20, 2026
AGIO-27.79%ANIP+57.44%
+133%+36%-62%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus ANIP key metrics
MetricAGIOANIP
Share price$27.60$68.55
Market cap$1.65B$1.56B
1-day change-4.03%-0.84%
YTD return+1.40%-13.16%
1-year return+9.35%-14.01%
5-year return-24.28%+68.14%
P/E ratio (TTM)—13.90
Forward P/E—6.72
EPS (TTM)$-6.31$4.93
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M$883.37M
Revenue growth (YoY)+48.03%+43.78%
Net income (latest FY)$-412.78M$78.34M
Gross margin88.26%61.36%
Operating margin-873.87%12.58%
Net margin-764.01%8.87%
52-week high$44.09$87.76
52-week low$24.16$67.14
Distance from 52-week high-37.40%-21.89%
Analyst consensusbuybuy
Avg. price target upside+67.07%+50.81%
Average volume1.06M420.66K
Shares outstanding59.81M22.72M
Employees539970
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AGIO has outperformed ANIP by 23.4 percentage points over the past year.
  • ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About ANI Pharmaceuticals

ANIP stock →

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees

AGIO vs ANIP FAQ

Which is bigger, Agios Pharmaceuticals or ANI Pharmaceuticals?

Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.65B compared with $1.56B for ANI Pharmaceuticals (ANIP).

Which stock has performed better over the past year, AGIO or ANIP?

AGIO returned +9.35% over the past 12 months, compared with -14.01% for ANIP (price return, excluding dividends). Past performance does not predict future results.

Are Agios Pharmaceuticals and ANI Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons